Replies to post #233842 on Biotech Values

[DewDiligence]

MRNA may have to invalidate ABUS patents on appeal to get around not paying license fees on its own mRNA vaccine.

The royalty MRNA may be required to pay to license the ABUS patents in question is likely in the single-digit range, which is consistent with MRNA’s price action today.

[RNsidersbuying]

ABUS 5.07 - here's the BNTX agreement with Genevant from 7/4/18:

https://www.sec.gov/Archives/edgar/data/1776985/000119312519241112/d635330dex1017.htm

Anyone here can decode this into layman-speak? Has it been updated?